[Market Summary]
The New York stock market closed mixed on January 7 (local time) as investors weighed diverging economic signals. While service sector activity showed unexpected strength, cooling labor data sparked caution regarding the Federal Reserve's next move.
Dow Jones: 48,996.08 (-466.00 pts, -0.94%)
S&P 500: 6,920.93 (-23.89 pts, -0.34%)
Nasdaq: 23,584.27 (+37.10 pts, +0.16%)
[Economic Pulse: Cooling Jobs vs. Resilient Services]
Market attention shifted from geopolitics to the Fed’s path. The JOLTS report showed job openings fell to 7.15 million in November, a one-year low, suggesting corporations are becoming more cautious amid policy uncertainty. ADP Private Employment also missed expectations, adding only 41,000 jobs.
Conversely, the ISM Services PMI surged to 54.4, far exceeding the expected 52.6. This resilience in services suggests that while the labor market is cooling, the broader economy remains in expansion territory.
[Major Analyst Ratings & Opinions]
In line with the latest market shifts, here are the key updates from major investment banks:
Eli Lilly (LLY): UBS initiated coverage with a Buy rating and a target of $1,250. Analysts highlighted Lilly's clear growth path in the obesity market and potential early launch of Orforglipron.
Micron Technology (MU): UBS maintained its Buy rating and hiked the target price to $400, citing DRAM as a "strategic asset" currently in severe shortage.
Uber (UBER): Bank of America maintained its Buy rating ($119 target), viewing Nvidia's autonomous vehicle (AV) initiatives as a major catalyst for Uber’s future network monetization.
SLB (SLB) & Halliburton (HAL): Evercore upgraded SLB to Outperform ($54) due to its Middle East exposure, while downgrading HAL to In-line ($35) citing risks in the slowing North American land market.
McDonald's (MCD): Oppenheimer upgraded the stock to Outperform ($355 target), noting that its 4% store growth target remains superior to competitors despite recent consumer spending headwinds.
Moderna (MRNA): UBS downgraded the stock to Neutral ($34 target) due to stagnant revenue growth and the high-risk nature of its upcoming melanoma vaccine trial results.
[Featured Stocks & Deep Dive]
■ Big Tech Headlines: Regulation and Restructuring
Nvidia (NVDA): Reports surfaced that the Chinese government requested local tech firms to pause orders of Nvidia H200 chips, favoring domestic alternatives. This comes despite the U.S. government previously approving H200 exports under a unique "revenue-sharing" tax condition.
Microsoft (MSFT): Rumors of a massive layoff (11,000 to 22,000 employees) in mid-January are circulating. The cuts target Azure Cloud and Xbox teams as MSFT refocuses its cost structure toward AI infrastructure. A stricter "return-to-office" mandate is also expected in February.
Meta Platforms (META): The $2 billion acquisition of Manners AI is facing delays as Chinese regulators review the deal for potential technology export violations.
Qualcomm (QCOM): Reportedly in talks with Samsung for 2nm chip production to challenge Intel and Apple in the growing AI PC market.
■ Healthcare: The M&A Wave
Eli Lilly (LLY): In final negotiations to acquire Ventyx Biosciences (VTYX) for $1 billion, aiming to strengthen its oral drug pipeline for inflammatory and metabolic diseases.
Amgen (AMZN): Acquired UK-based Dark Blue Therapeutics for $840 million to bolster its oncology protein degradation portfolio.
■ Consumer, Retail, and Energy
Chevron (CVX): Reviewing a $22 billion joint acquisition with Quantum Capital of Lukoil's international assets, including over 2,000 gas stations and refineries globally.
Spotify (SPOT): Expanding into the video creator ecosystem to rival YouTube by lowering barriers for video podcast monetization.
Boeing (BA): Secured its largest-ever order from Alaska Air for 105 737 Max 10 and 5 787-10 Dreamliner aircraft.
Defense Stocks (GD, LMT, NOC): Faced pressure following President Trump's comments regarding prohibiting buybacks/dividends and capping executive pay for defense contractors until new factories are built.
[After-Hours Watchlist]
Globus Medical (GMED): +9% after raising its forward guidance.
Ventyx Bio (VTYX): Skyrocketed on reports of the Lilly acquisition.
Revolution Medicine (RVMD): -13% after AbbVie denied acquisition rumors.
Constellation Brands (STZ): +2.8% on a Q3 earnings beat.
